- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Human immunodeficiency virus (HIV) infection
- Meeting Date: July 2020
- Public Summary Document (PSD) July 2020 PBAC Meeting - (PDF 1156KB)
- Public Summary Document (PSD) July 2020 PBAC Meeting - (Word 85KB)
Dolutegravir with lamivudine – July 2020
Dolutegravir with Lamivudine: Tablet containing dolutegravir 50 mg (as sodium) with lamivudine 300 mg; Dovato®
Last updated
30 October 2020